CD7 and neoplasm: To cope with the negative recurrence of tumor patients after CD7 CAR-T treatment, it may be an excellent solution to find new targetsCD5 CAR T-cells may be a practical choice, and its efficacy in the treatment of T-cell malignant tumors has been verified in past experiments.